MIAMI--(BUSINESS WIRE)--Data presented at the 6th Annual Human Amyloid Imaging (HAI) meeting in Miami suggest that the investigational imaging agent [18F] Flutemetamol could add value to current diagnostic tools used by physicians to evaluate neurodegenerative conditions like Alzheimer’s Disease (AD). [18F]Flutemetamol is a GE Healthcare PET imaging agent in phase III development for the detection of beta amyloid.
